Multiple sclerosis and spinal cord ischemia were the top two diagnoses.
Idiopathic transverse myelitis (ITM) is defined as an inflammatory myelopathy of undetermined etiology that peaks clinically between 4 hours and 21 days after onset, with clear myelopathic signs on exam and MRI and no etiology after a thorough work-up.
Neurologists at the Mayo Clinic reviewed records from 226 patients seen or referred with a presumptive diagnosis of ITM. After evaluation, only 18% had confirmation of ITM. A myelopathic etiology was determined in 70%; 12% did not have myelopathy confirmed (9% nonneurologic/functional, almost 4% neurologic but not myelopathic).
Inflammatory myelopathies were diagnosed in 46% of referrals: multiple sclerosis in 33%, neurosarcoidosis in 5%, neuromyelitis optica spectrum disorder (NMOSD) in 5%, my…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)